Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet

The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Sep 1, 2025, 1:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2025, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet — source image
Decision brief

The 30-second read

$PASGBullishMed
01

Why it matters

The positive analyst consensus could lead to increased trading volume and speculative buying, but underlying fundamentals and clinical progress should be closely monitored.

02

Market read

The news is highly relevant for biotech investors and traders focusing on gene therapy stocks, with potential for significant short-term price movements.

03

What to watch

Potential regulatory hurdles, clinical trial outcomes, and market competition could significantly impact the stock's actual performance.

Relevance 6/10Timing: Short to medium-term (next 3-6 months)

Background

Passage Bio has received analyst attention due to recent earnings estimate revisions and sector interest.

Company-level read

Ticker impact

$PASGBullishMedium confidence
Context

High relevance due to analyst consensus and significant upside potential.

Expected impact

Potential substantial increase in stock price, possibly exceeding 700% in the short to medium term.

Evidence & confidence

While the consensus among analysts indicates a strong upside, the historical reliability of analyst target averages for such magnitude is questionable. The positive sentiment and earnings revisions support optimism, but the extraordinary percentage warrants caution.

Market effects

Potential positive impact on the Life Sciences sector, especially biotech firms with similar profiles.

Limited regional impact; primarily relevant to US biotech market.

Moderate; biotech sector is globally interconnected, but specific to US-based Passage Bio.

Counterpoint

The projected 731% surge may be overly optimistic; historical data shows such targets often do not materialize, and biotech stocks are highly volatile.

Key entities

  • Passage Bio

    Biotech company focused on gene therapies for rare diseases.

  • Zacks Equity Research

    Provider of financial research and analysis.

Related articles

$PASGMed

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.